Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance

John A. Katzenellenbogen, Christopher G. Mayne, Benita S Katzenellenbogen, Geoffrey L. Greene, Sarat Chandarlapaty

Research output: Contribution to journalReview article

Abstract

Oestrogen receptor-α (ERα), a key driver of breast cancer, normally requires oestrogen for activation. Mutations that constitutively activate ERα without the need for hormone binding are frequently found in endocrine-therapy-resistant breast cancer metastases and are associated with poor patient outcomes. The location of these mutations in the ER ligand-binding domain and their impact on receptor conformation suggest that they subvert distinct mechanisms that normally maintain the low basal state of wild-type ERα in the absence of hormone. Such mutations provide opportunities to probe fundamental issues underlying ligand-mediated control of ERα activity. Instructive contrasts between these ERα mutations and those that arise in the androgen receptor (AR) during anti-androgen treatment of prostate cancer highlight differences in how activation functions in ERs and AR control receptor activity, how hormonal pressures (deprivation versus antagonism) drive the selection of phenotypically different mutants, how altered protein conformations can reduce antagonist potency and how altered ligand-receptor contacts can invert the response that a receptor has to an agonist ligand versus an antagonist ligand. A deeper understanding of how ligand regulation of receptor conformation is linked to receptor function offers a conceptual framework for developing new anti-oestrogens that might be more effective in preventing and treating breast cancer.

Original languageEnglish (US)
Pages (from-to)377-388
Number of pages12
JournalNature Reviews Cancer
Volume18
Issue number6
DOIs
StatePublished - Jun 1 2018

Fingerprint

Estrogen Receptors
Ligands
Mutation
Androgen Receptors
Breast Neoplasms
Estrogens
Therapeutics
Hormones
Protein Conformation
Mutant Proteins
Androgens
Prostatic Neoplasms
Neoplasm Metastasis
Pressure

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance. / Katzenellenbogen, John A.; Mayne, Christopher G.; Katzenellenbogen, Benita S; Greene, Geoffrey L.; Chandarlapaty, Sarat.

In: Nature Reviews Cancer, Vol. 18, No. 6, 01.06.2018, p. 377-388.

Research output: Contribution to journalReview article

Katzenellenbogen, John A. ; Mayne, Christopher G. ; Katzenellenbogen, Benita S ; Greene, Geoffrey L. ; Chandarlapaty, Sarat. / Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance. In: Nature Reviews Cancer. 2018 ; Vol. 18, No. 6. pp. 377-388.
@article{935335fa2cdd44bfa8be1827688c76a6,
title = "Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance",
abstract = "Oestrogen receptor-α (ERα), a key driver of breast cancer, normally requires oestrogen for activation. Mutations that constitutively activate ERα without the need for hormone binding are frequently found in endocrine-therapy-resistant breast cancer metastases and are associated with poor patient outcomes. The location of these mutations in the ER ligand-binding domain and their impact on receptor conformation suggest that they subvert distinct mechanisms that normally maintain the low basal state of wild-type ERα in the absence of hormone. Such mutations provide opportunities to probe fundamental issues underlying ligand-mediated control of ERα activity. Instructive contrasts between these ERα mutations and those that arise in the androgen receptor (AR) during anti-androgen treatment of prostate cancer highlight differences in how activation functions in ERs and AR control receptor activity, how hormonal pressures (deprivation versus antagonism) drive the selection of phenotypically different mutants, how altered protein conformations can reduce antagonist potency and how altered ligand-receptor contacts can invert the response that a receptor has to an agonist ligand versus an antagonist ligand. A deeper understanding of how ligand regulation of receptor conformation is linked to receptor function offers a conceptual framework for developing new anti-oestrogens that might be more effective in preventing and treating breast cancer.",
author = "Katzenellenbogen, {John A.} and Mayne, {Christopher G.} and Katzenellenbogen, {Benita S} and Greene, {Geoffrey L.} and Sarat Chandarlapaty",
year = "2018",
month = "6",
day = "1",
doi = "10.1038/s41568-018-0001-z",
language = "English (US)",
volume = "18",
pages = "377--388",
journal = "Nature Reviews Cancer",
issn = "1474-175X",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance

AU - Katzenellenbogen, John A.

AU - Mayne, Christopher G.

AU - Katzenellenbogen, Benita S

AU - Greene, Geoffrey L.

AU - Chandarlapaty, Sarat

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Oestrogen receptor-α (ERα), a key driver of breast cancer, normally requires oestrogen for activation. Mutations that constitutively activate ERα without the need for hormone binding are frequently found in endocrine-therapy-resistant breast cancer metastases and are associated with poor patient outcomes. The location of these mutations in the ER ligand-binding domain and their impact on receptor conformation suggest that they subvert distinct mechanisms that normally maintain the low basal state of wild-type ERα in the absence of hormone. Such mutations provide opportunities to probe fundamental issues underlying ligand-mediated control of ERα activity. Instructive contrasts between these ERα mutations and those that arise in the androgen receptor (AR) during anti-androgen treatment of prostate cancer highlight differences in how activation functions in ERs and AR control receptor activity, how hormonal pressures (deprivation versus antagonism) drive the selection of phenotypically different mutants, how altered protein conformations can reduce antagonist potency and how altered ligand-receptor contacts can invert the response that a receptor has to an agonist ligand versus an antagonist ligand. A deeper understanding of how ligand regulation of receptor conformation is linked to receptor function offers a conceptual framework for developing new anti-oestrogens that might be more effective in preventing and treating breast cancer.

AB - Oestrogen receptor-α (ERα), a key driver of breast cancer, normally requires oestrogen for activation. Mutations that constitutively activate ERα without the need for hormone binding are frequently found in endocrine-therapy-resistant breast cancer metastases and are associated with poor patient outcomes. The location of these mutations in the ER ligand-binding domain and their impact on receptor conformation suggest that they subvert distinct mechanisms that normally maintain the low basal state of wild-type ERα in the absence of hormone. Such mutations provide opportunities to probe fundamental issues underlying ligand-mediated control of ERα activity. Instructive contrasts between these ERα mutations and those that arise in the androgen receptor (AR) during anti-androgen treatment of prostate cancer highlight differences in how activation functions in ERs and AR control receptor activity, how hormonal pressures (deprivation versus antagonism) drive the selection of phenotypically different mutants, how altered protein conformations can reduce antagonist potency and how altered ligand-receptor contacts can invert the response that a receptor has to an agonist ligand versus an antagonist ligand. A deeper understanding of how ligand regulation of receptor conformation is linked to receptor function offers a conceptual framework for developing new anti-oestrogens that might be more effective in preventing and treating breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=85045418167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045418167&partnerID=8YFLogxK

U2 - 10.1038/s41568-018-0001-z

DO - 10.1038/s41568-018-0001-z

M3 - Review article

C2 - 29662238

AN - SCOPUS:85045418167

VL - 18

SP - 377

EP - 388

JO - Nature Reviews Cancer

JF - Nature Reviews Cancer

SN - 1474-175X

IS - 6

ER -